View Older Stories View More Recent Stories

Jun 3, 2025 08:13AM Kymera Therapeutics (KYMR) PT Raised to $68 at Stifel
Jun 3, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Jun 3, 2025 04:49AM Wells Fargo Reiterates Overweight Rating on Kymera Therapeutics (KYMR)
Jun 3, 2025 03:31AM B.Riley Upgrades Kymera Therapeutics (KYMR) to Buy
Jun 3, 2025 03:19AM Morgan Stanley Upgrades Kymera Therapeutics (KYMR) to Overweight
Jun 2, 2025 03:39PM Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Data
Jun 2, 2025 02:09PM Kymera Therapeutics (KYMR) PT Raised to $60 at Citi
Jun 2, 2025 02:06PM BofA Securities Upgrades Kymera Therapeutics (KYMR) to Buy
Jun 2, 2025 09:55AM Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Data
Jun 2, 2025 08:04AM Citi Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Jun 2, 2025 07:00AM Kymera Therapeutics (KYMR) Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
May 30, 2025 04:02PM Kymera Therapeutics (KYMR) to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
May 20, 2025 04:28AM Stifel Resumes Kymera Therapeutics (KYMR) at Buy
May 19, 2025 12:15PM Kymera Therapeutics (KYMR) Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
May 12, 2025 08:14AM Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR)
May 12, 2025 06:11AM Kymera Therapeutics (KYMR) PT Lowered to $55 at BTIG
May 9, 2025 01:57PM Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR) Following Q1 Update
May 9, 2025 07:21AM Kymera Therapeutics (KYMR) Tops Q1 EPS by 7c
May 9, 2025 07:04AM Kymera Therapeutics (KYMR) Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
Apr 29, 2025 05:58PM Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) ahead of June readout
Apr 9, 2025 07:01AM Kymera Therapeutics (KYMR) Appoints Noah Goodman as Chief Business Officer
Feb 28, 2025 10:57AM Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Feb 28, 2025 10:01AM UBS Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Feb 28, 2025 07:14AM Kymera Therapeutics (KYMR) PT Lowered to $54 at H.C. Wainwright
Feb 27, 2025 07:07AM Kymera Therapeutics (KYMR) Misses Q4 EPS by 11c
Feb 19, 2025 09:16AM NAYA Biosciences (NAYA) nominates new Board members
Jan 14, 2025 07:01AM Kymera Therapeutics (KYMR) Outlines Key 2025 Objectives and Strategy
Jan 8, 2025 09:09AM Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR) Amid 'Bold Strategy'
Dec 5, 2024 04:08PM BMO Capital Starts Kymera Therapeutics (KYMR) at Market Perform
Dec 2, 2024 06:44AM Wells Fargo Upgrades Kymera Therapeutics (KYMR) to Overweight
Nov 1, 2024 07:58AM Kymera Therapeutics (KYMR) PT Raised to $56 at Stifel
Nov 1, 2024 05:59AM Kymera Therapeutics (KYMR) PT Raised to $41 at B.Riley
Oct 31, 2024 04:11PM Kymera Therapeutics (KYMR) PT Raised to $59 at Jefferies
Oct 31, 2024 07:36AM Kymera Therapeutics (KYMR) Tops Q3 EPS by 1c
Oct 9, 2024 07:01AM Kymera Therapeutics (KYMR) Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
Sep 27, 2024 06:32AM Kymera Therapeutics (KYMR) PT Raised to $56 at Oppenheimer
Sep 25, 2024 07:01AM Kymera Therapeutics (KYMR) Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Sep 9, 2024 12:07PM Leerink Partners Assumes Kymera Therapeutics (KYMR) at Outperform, 'We have a more cautious view on KT-474'
Aug 26, 2024 02:55PM Kymera Therapeutics (KYMR) October 50 puts active on bid
Aug 26, 2024 06:03AM Wolfe Research Upgrades Kymera Therapeutics (KYMR) to Outperform
Aug 20, 2024 06:12AM Kymera Therapeutics (KYMR) Prices $225M Offering at $40.75/sh
Aug 19, 2024 04:01PM Kymera Therapeutics (KYMR) Announces $200M Proposed Public Offering
Aug 8, 2024 06:37AM Kymera Therapeutics (KYMR) PT Raised to $60 at H.C. Wainwright
Aug 7, 2024 07:49AM Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c
Jul 9, 2024 07:35AM Kymera Therapeutics (KYMR) PT Raised to $36 at B.Riley
Jul 9, 2024 07:27AM TD Cowen Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Jul 8, 2024 05:10PM After-hours movers: Intel, Helios, Zapp Electric Vehicles Group and more
Jul 8, 2024 04:05PM Kymera Therapeutics (KYMR) Announces Expansion of KT-474 HS and AD Phase 2 Studies
Jun 17, 2024 08:17AM Piper Sandler Reiterates Overweight Rating on Kymera Therapeutics (KYMR)
Jun 17, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)
View More Recent Stories View Older Stories